Table 2 Treatment-related adverse events

From: Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer

 

No. of patients (%)

Event

Grade 1/2

Grade 3/4

Anaemia

21 (44%)

2 (4%)

Neutropenia

6 (13%)

4 (8%)

Febrile neutropenia

NA

2 (4%)

Thrombocytopenia

7 (15%)

1 (2%)

Diarrhoea

17 (35%)

8 (17%)

Constipation

4 (8%)

0 (0%)

Stomatitis

7 (15%)

0 (0%)

Nausea

33 (69%)

3 (6%)

Emesis

13 (27%)

1 (2%)

Fatigue

21 (44%)

2 (4%)

Deep vein thrombosis

NA

7 (15%)

Tumour bleeding

NA

2 (4%)

Cardiac ischaemia

NA

1 (2%)

Pneumonia

NA

1 (2%)

Fever

4 (8%)

0 (0%)

Alopecia

7 (15%)

NA

Sensory neuropathy

32 (67%)

0 (0%)

  1. NA=not applicable.